Brain Health

The results found that women, non-binary, and sexual minority students are at the highest risk.

If approved, the investigational intravenous gene therapy will be the first disease-modifying therapy for developmental and epileptic encephalopathy (DEE).

The investigators found that the SRGAP2 and SYNGAP1 genes act together to control the speed of human synapse development, which has impacts on neurodevelopmental disease pathways.

The FDA announces a Class II recall for the lot #220128, which were reported to contain the presence of nitrosamine.

Women are more likely to face burnout because they are often balancing both workload and family or home life responsibilities.

Disruptions in the salience network function are shown to influence the severity of mild behavioral impairment (MBI) symptoms.

Patients aged 7 years and older can now be treated for their cataplexy or excessive daytime sleepiness with the extended-release oral formulation.

This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.

Video chatting, texting, watching videos, and playing video games were activities most commonly associated with depressive symptoms in adolescents.

According to the authors, being able to identify mood disturbances through passive digital biomarker data can be promising in next-generation predictive, personalized mental health diagnostics.

Poor sleep quality is directly related to mortality risk before adjusting for lifestyle or health-related factors, and dementia was noticeably linked to mortality risk in older White males.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

The authors note this is the first study to assess cerebrovascular endothelial extracellular vesicles within a cognitive condition.

Using the term "pseudodementia" contributes to the mismanagement and mistreatment of the disease.

Additionally, the authors are concerned by the lack of increase in depressive or anxiety diagnoses, indicating potential barriers to care.

The authors urge that screening, prevention, and treatment of anxiety and depression should be important health care priorities for youth who have chronic pain.

The findings demonstrate a need for additional health care provider training and resources for birthing people with intellectual and developmental disabilities.

Those with an aneurysm diagnosis who were younger than 40 years of age were observed to have an even higher risk.

The study may serve as a foundation for future investigation regarding dietary recommendations to support the treatment of Alzheimer disease.

Findings from 2 large datasets suggest hormone therapy may reduce Alzheimer risk, hippocampal atrophy, and cerebrovascular disease.

Significant commonalities between type 2 diabetes and neurodegenerative disorders suggest that treatments effective for one condition may benefit the other.

This marks the first FDA-approved systemic therapy for patients with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IHD1) or IDH2 mutation.

Improvements were observed in both the intervention and control group, with those who had self-reported learning difficulties showing the least improvement.

Study results demonstrated that lecanemab provided sustained benefits over 36 months, such as improved biomarker profiles and slowed cognitive decline compared with placebo.

The findings indicate that zoster vaccine recombinant reduced dementia risk by 17% in an analysis of over 200,000 patients.

The study also found that there were no associations with increased dementia risk when anxiety resolved.

Benzgalantamine (Zunveyl; Alpha Cognition) is a cholinesterase inhibitor indicated for the treatment of mild-to-moderate dementia in adults.

The findings also demonstrate that body dysmorphic disorder is also associated with high levels of comorbid psychopathology, risk, and psychosocial impairment.

Safety and efficacy findings on Lomecel-B will be presented at the upcoming 2024 Alzheimer’s Association International Conference, which will be held July 28 to August 1.

The authors note that the oral, at-home treatment can be a better alternative for patients by reducing inconveniences that come with the injectable and nasal administration methods.